androgen receptor antagonist; androgen receptor signaling inhibitor (ARSI)
Jump to navigation
Jump to search
Adverse effects
- increased risk of cardiovascular events when used in combination with conventional androgen deprivation therapy[1]
More general terms
More specific terms
- apalutamide (Erleada)
- bicalutamide (Casodex)
- clascoterone (Cassiopea, Breezula, Winlevi)
- darolutamide (Nubeqa)
- enzalutamide (Xtandi)
- flutamide (Eulexin, Niftholide)
- nilutamide (Nilandron)
Additional terms
- androgen or anabolic steroid
- androgen receptor; dihydrotestosterone receptor; nuclear receptor subfamily 3 group C member 4 (AR, DHTR, NR3C4)
References
- ↑ 1.0 1.1 El-Taji O, Taktak S, Jones C, et al. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024 Jun 6:e241549. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38842801 PMCID: PMC11157448 (available on 2025-06-06) https://jamanetwork.com/journals/jamaoncology/fullarticle/2819647